Notice: This company has been marked as potentially delisted and may not be actively trading. Forma Therapeutics (FMTX) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Trading was temporarily halted for "FMTX" at 07:10 PM with a stated reason of "News pending."October 14, 2022 | marketbeat.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Receives Average Rating of "Hold" from BrokeragesForma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) has earned an average recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The aSeptember 27, 2022 | marketbeat.comForma Therapeutics Holdings, Inc. (FMTX)September 25, 2022 | finance.yahoo.comBiotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreSeptember 7, 2022 | finance.yahoo.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates GMTX, FMTX, SGFY, ECOMSeptember 7, 2022 | apnews.comThe M&A Class Action Firm Announces the Investigation of Forma Therapeutics Holdings, Inc. - FMTXSeptember 7, 2022 | benzinga.com4 Analysts Have This to Say About Forma Therapeutics HldgsSeptember 2, 2022 | markets.businessinsider.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by BrokeragesForma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) has earned a consensus rating of "Hold" from the six research firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation tSeptember 2, 2022 | marketbeat.comForma Therapeutics (NASDAQ:FMTX) Downgraded by HC WainwrightHC Wainwright cut Forma Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday.September 2, 2022 | marketbeat.comForma Therapeutics: Rare Disease PlaySeptember 2, 2022 | seekingalpha.comNovo Nordisk To Acquire Forma Therapeutics - Quick FactsSeptember 1, 2022 | markets.businessinsider.comNovo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disordersSeptember 1, 2022 | finance.yahoo.comNovo Nordisk to Buy Forma Therapeutics for $1.1 Billion >FMTX NVOSeptember 1, 2022 | marketwatch.comFMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to ShareholdersSeptember 1, 2022 | apnews.comForma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billionSeptember 1, 2022 | finance.yahoo.comUPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln dealSeptember 1, 2022 | finance.yahoo.comTrading was temporarily halted for "FMTX" at 07:09 AM with a stated reason of "News pending."September 1, 2022 | marketbeat.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Short Interest Down 8.8% in AugustForma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) was the recipient of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,650,000 shares, a drop of 8.8% from the July 31st total of 1,810,000 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 542,500 shares, the short-interest ratio is presently 3.0 days.August 31, 2022 | marketbeat.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) up 28%, but insiders miss out having sold stock earlier this yearAugust 11, 2022 | nasdaq.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) to Post FY2022 Earnings of ($4.19) Per Share, Cantor Fitzgerald ForecastsForma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities researchers at Cantor Fitzgerald raised their FY2022 earnings estimates for shares of Forma Therapeutics in a research note issued to investors on Monday, August 8th. Cantor Fitzgerald analyst P. Agrawal now anticipates thatAugust 10, 2022 | marketbeat.comForma Therapeutics (NASDAQ:FMTX) Price Target Cut to $33.00 by Analysts at Credit Suisse GroupCredit Suisse Group reduced their target price on shares of Forma Therapeutics to $33.00 in a report on Tuesday.August 9, 2022 | marketbeat.comRigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing PactAugust 3, 2022 | msn.comRigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid LeukemiaAugust 2, 2022 | finance.yahoo.comForma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022July 29, 2022 | finance.yahoo.comForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Sees Significant Decline in Short InterestForma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 1,910,000 shares, a drop of 33.9% from the June 15th total of 2,890,000 shares. Based on an average daily trading volume, of 593,000 shares, the short-interest ratio is currently 3.2 days. Currently, 4.6% of the company's stock are sold short.July 17, 2022 | marketbeat.comForma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 12, 2022 | finance.yahoo.comHow Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 379%July 8, 2022 | finance.yahoo.comForma Therapeutics Announces Appointment of New Executive Team MembersJune 30, 2022 | finance.yahoo.comCan Forma Therapeutics Holdings, Inc. (FMTX) Climb 536% to Reach the Level Wall Street Analysts Expect?June 22, 2022 | finance.yahoo.comBears are Losing Control Over Forma Therapeutics Holdings, Inc. (FMTX), Here's Why It's a 'Buy' NowJune 15, 2022 | finance.yahoo.comCantor Fitzgerald Comments on Forma Therapeutics Holdings, Inc.'s FY2022 Earnings (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities research analysts at Cantor Fitzgerald increased their FY2022 earnings per share (EPS) estimates for shares of Forma Therapeutics in a report issued on Monday, June 13th. Cantor Fitzgerald analyst P. Agrawal now anticipates tJune 15, 2022 | marketbeat.comRead Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'June 13, 2022 | finance.yahoo.comForma Therapeutics Holdings, Inc. to Post FY2023 Earnings of ($3.47) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Cantor Fitzgerald issued their FY2023 earnings per share estimates for Forma Therapeutics in a report released on Monday, June 6th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($3.47) per sharJune 8, 2022 | marketbeat.comForma Therapeutics to Present at the Jefferies Healthcare ConferenceJune 3, 2022 | finance.yahoo.comForma Therapeutics (NASDAQ:FMTX) Lifted to "Buy" at Zacks Investment ResearchZacks Investment Research upgraded shares of Forma Therapeutics from a "hold" rating to a "buy" rating and set a $6.25 price target on the stock in a research report on Monday.May 30, 2022 | marketbeat.comForma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) DayMay 26, 2022 | finance.yahoo.comForma Therapeutics Holdings, Inc. to Post FY2022 Earnings of ($4.86) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:FMTX)Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Forma Therapeutics in a research note issued to investors on Monday, May 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will postMay 12, 2022 | marketbeat.comForma Therapeutics' (FMTX) Overweight Rating Reaffirmed at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Forma Therapeutics in a report on Monday.May 12, 2022 | marketbeat.comCompanies Like Forma Therapeutics Holdings (NASDAQ:FMTX) Are In A Position To Invest In GrowthMay 8, 2022 | finance.yahoo.comForma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q1 2022 Results - Earnings Call TranscriptMay 6, 2022 | seekingalpha.comForma Therapeutics Holdings Tops Q1 EPS by 12cMay 6, 2022 | investing.comForma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 6, 2022 | finance.yahoo.comPreview: Forma Therapeutics Hldgs's EarningsMay 5, 2022 | benzinga.comForma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022April 29, 2022 | finance.yahoo.comForma Therapeutics: Q4 Earnings InsightsMarch 1, 2022 | benzinga.comForma Therapeutics GAAP EPS of -$1.06 misses by $0.10March 1, 2022 | seekingalpha.comForma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdateMarch 1, 2022 | finance.yahoo.comForma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022February 23, 2022 | finance.yahoo.comForma Therapeutics to Present at 11th Annual SVB Leerink Healthcare ConferenceFebruary 8, 2022 | finance.yahoo.comForma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D CommitteeJanuary 13, 2022 | finance.yahoo.com Get Forma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Rare "crisis signal" triggers for third time in U.S. market (Ad)A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years. Click here for all the details. FMTX Media Mentions By Week FMTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FMTX News Sentiment▼0.000.61▲Average Medical News Sentiment FMTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FMTX Articles This Week▼00▲FMTX Articles Average Week Get Forma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRSP News Today DNLI News Today TWST News Today SWTX News Today VCEL News Today KYMR News Today IOVA News Today BEAM News Today RXRX News Today APGE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FMTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forma Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.